FDA Approves USA’s First Interchangeable Biosimilar Insulin Product for Diabetes
The Food and Drug Administration of the United States have now approved the first interchangeable biosimilar insulin product, that is mainly indicated for the purpose of improving the glycemic control in the pediatric and adults affected from the Type 1 diabetes and in the adults affected with Type 2 diabetes. The product ‘Semglee’ has been […]
Continue Reading